A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202.

Authors

Aarti K. Bhatia

Yale School of Medicine & Yale Cancer Center, New Haven, CT

Aarti K. Bhatia , Yael Flamand , Jennifer Maria Johnson , Jeffrey Joseph Ishizuka , Fenghai Duan , Mei Tang , Vidhya Karivedu , Rathan M. Subramaniam , Barbara Burtness

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

First Author: Zev A. Wainberg

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.

First Author: Majd Issa

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).

First Author: Marc Thomas Roth

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.

First Author: Christine H. Chung